Advanced Esophageal Cancer: Pembrolizumab plus Chemotherapy as First-line Therapy

被引：0
|
作者：
Franke, Katharina
机构：
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2021年 / 59卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1255 / +
页数：2
相关论文
共 50 条
  • [21] Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer
    Michalaki, V.
    ANNALS OF ONCOLOGY, 2008, 19 : I45 - I45
  • [22] First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer
    Park, SH
    Bang, SM
    Cho, EK
    Baek, JH
    Oh, JH
    Im, SA
    Park, YS
    Shin, DB
    Lee, JH
    ONCOLOGY, 2004, 66 (05) : 353 - 357
  • [23] Irinotecan plus capecitabine as first-line chemotherapy in advanced colorectal cancer
    Gennatas, C.
    Michalaki, V.
    Gennatas, S.
    Papalambros, E.
    ANTICANCER RESEARCH, 2008, 28 (3B) : 1923 - 1926
  • [24] Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer
    Hirose, Toshiharu
    Yamamoto, Shun
    Kato, Ken
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
  • [25] Pembrolizumab as a first-line treatment for advanced gastric cancer
    Chau, Ian
    LANCET ONCOLOGY, 2023, 24 (11): : 1158 - 1159
  • [26] Pembrolizumab plus axitinib beyond first-line therapy for mRCC
    Thomas, Tim
    NATURE REVIEWS UROLOGY, 2023, 20 (3) : 131 - 131
  • [27] Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study.
    Mansoor, Wasat
    Kulkarni, Amit S.
    Kato, Ken
    Sun, Jong-Mu
    Shah, Manish A.
    Enzinger, Peter C.
    Adenis, Antoine
    Doi, Toshihiko
    Kojima, Takashi
    Metges, Jean-Philippe
    Li Zhigang
    Kim, Sung-Bae
    Cho, Byoung Chul
    Sunpaweravong, Patrapim
    Alsina, Maria
    Goekkurt, Eray
    Suryawanshi, Shailaja
    Norquist, Josephine
    Shah, Sukrut
    Shen Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [28] First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis
    Cao, Xueqiong
    Cai, Hongfu
    Li, Na
    Zheng, Bin
    Zheng, Zhiwei
    Liu, Maobai
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [29] FOLFOX plus cetuximab in first-line therapy of advanced colorectal cancer
    Ehrenberg, Roland
    Halama, Niels
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [30] Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer
    Delfino, C
    Caccia, G
    Gonzáles, LR
    Mickiewicz, E
    Rodger, J
    Balbiani, L
    Morales, DF
    Comba, AZ
    Brosio, C
    ONCOLOGY, 2004, 66 (01) : 18 - 23
12345